Navigation Links
M. D. Anderson study questions true favorability of rare breast cancer type
Date:12/12/2009

SAN ANTONIO - In a large review of breast cancer patients with mucinous carcinoma, researchers at The University of Texas M. D. Anderson Cancer Center have identified an association between this rare type of breast cancer long-associated with a favorable prognosis and multiple tumors undetected by mammography or ultrasound.

The study, presented today at the CTRC-AACR San Antonio Breast Cancer Symposium, is the first to observe this negative association and should caution those caring for mucinous breast cancer patients that more, not less, therapy, as well as additional screening may be needed for a select group of these patients, said George Perkins, M.D., associate professor in M. D. Anderson Department of Radiation Oncology and the study's first author.

Mucinous breast cancer, also known as colloid carcinoma, is a rare type of invasive breast cancer formed by mucus-producing cancer cells. Perkins estimated that the disease accounts for approximately two percent of all breast cancers diagnosed. The prognosis for mucinous carcinoma is thought to be better than for the more common types of invasive breast cancers.

"While mucinous breast cancer is thought to be a disease with a favorable prognosis, our study is the first to identify it as one associated with significant multifocal presentation - a potentially unfavorable aspect with a subtype long thought to be extremely favorable," said Perkins. "Our findings must caution those caring for these women that they may not only need more radiographic evaluation, such as MRI, but also intraoperative collaboration with radiology and pathology. These patients also may need standard radiation treatment, rather than the minimal effective therapy, which could include no post-surgery treatment at all."

Researchers reviewed charts of 264 patients with mucinous carcinoma treated at M. D. Anderson between 1965 and 2005. The median age and follow-up was 57 years and 168 months respectively. Of the patients, 86 percent were stage T2 or less, and 80 percent had no lymph node involvement, 15 percent had 1-3 positive nodes and 5 percent had 4 or more.

Regarding treatment, 44 percent of the women received breast-conserving therapy, and the rest underwent a mastectomy; 51 percent had radiation.

However, while 10 percent of the women first presented with more than one tumor, after surgical resection and complete pathological review, the actual rate of multifocal disease was 38 percent. None of these tumors were detected by mammography and/or ultrasound.

"This actual rate of multifocal disease was a tremendous surprise and of true concern," said Perkins. "We are also concerned that the age of disease presentation appears to be decreasing in this population. Combined with this trend of unfavorability, it's imperative that we continue to research personalized treatment options for this subtype and that patients receive their treatment based on actual presentation rather than the assumption that this is always a favorable disease."

The five, 10 and 15 year overall survival (OS), disease-free survival (DFMS), local-regional control (LRC) were: 95 percent, 88 percent, 83 percent; 97 percent, 95 percent, 92 percent and 97 percent, 94 percent and 85 percent, respectively. When analyzing surgical options, there was no statistically significant difference in overall OS, DFMS, or LRS. Likewise, there was no improvement in OS or DMFS in patients that received whole breast radiation. There was a trend, however, for improved LRC in patients who received radiation when comparing patients that underwent surgery without radiation.

As follow up, the researchers are evaluating a subtype of mucinous breast cancer thought to be exceedingly aggressive in hopes of establishing specific screening and treatment guidelines.


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. New funds for Rice, M.D. Anderson program
2. Celebrity Trainer Tracy Anderson Sharing Her Fitness and Diet Secrets This Week
3. Radiation Therapy Options in Mesothelioma by Veronica Garza of MD Anderson Sponsored by MesoCare.org
4. Green tea shows promise as chemoprevention agent for oral cancer, M. D. Anderson study finds
5. M. D. Anderson redefines screening guidelines for breast, cervical and colorectal cancers
6. M. D. Anderson team chosen to help navigate Cancer Genome Atlas
7. Mesothelioma Surgical Update by Dr. David Rice MD Anderson Sponsored by MesoCare.org
8. M. D. Anderson scientist wins NIH New Innovator Award
9. M. D. Anderson examines use of toad venom in cancer treatment
10. Tampa Personal Injury Lawyer Timothy Anderson, Jr. Joins Father's Law Firm, Takes Five Cases To Jury Trial In First Eighteen Months
11. Anderson: Industry Advocacy, Engagement Key to Healthcare Reform
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
M. D. Anderson study questions true favorability of rare breast cancer type
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: